Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks

CONCLUSION: In HAVEN 1 to 4, emicizumab demonstrated sustained PKs and PDs and improved coagulation parameters without affecting safety biomarkers.PMID:38282901 | PMC:PMC10818085 | DOI:10.1016/j.rpth.2023.102306

Source: Thrombosis and Haemostasis - January 29, 2024 Category: Hematology Authors: Anna Kiialainen Joanne I Adamkewicz Claire Petry Johannes Oldenburg Steven W Pipe Guy Young Johnny Mahlangu Michaela Lehle Markus Niggli Giancarlo Castaman V íctor Jiménez-Yuste Midori Shima Claude N égrier Christophe Schmitt Source Type: research